YN370298 Gcase activator 1 1919820-28-2

LTI-291 is the first small-molecule activator of Glucocerebrosidase(GCase) for the treatment of parkinson's disease.

YN350092 MW-150 hydrochloride 1923773-01-6

MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor ofp38α MAPKwith a Ki of 101nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability...

YN420178 PQR626 1927857-98-4

PQR626 is an orally available, and brain-penetrantmTORinhibitor extracted from patent WO2017198346A1, compound example 44, has an IC50 of 5nM for mTOR. PQR626 can be used for the research of neurological disorder.

YN360327 ML418 1928763-08-9

ML418 is the first potent, selective and CNS penetrating blocker ofKir7.1 potassium channel(IC50, 310nM), which also potently inhibits Kir6.2/SUR1, and exhibits superior selectivity over other Kir channels.

YN360447 MDR-652 1933528-96-1

MDR-652 is a highly specific and efficacioustransient receptor potential vanilloid 1(TRPV1) lig and with agonist activity. TheKis are 11.4 and 23.8nM for hTRPV1 and rTRPV1, respectively. TheEC50s are 5.05 and 9...

YN320767 PM226 1949726-13-9

PM226 is a selectivecannabinoid CB2Ragonist (Ki(CB2R)=13nM;EC50(CB2R)=39nM; Ki(CB1R) >40μM;) with neuroprotective properties in vitro and vivo.

YN480697 GSK 366 1953157-39-5

GSK 366 is a potentkynurenine-3-monooxygenase (KMO)inhibitor with IC50s of 2.3nM and 0.7nM for human KMO and P. fluorescens-KMO (Pf-KMO), respectively.

YN1730037 Xanthine amine congener dihyd... 1962928-23-9

Xanthine amine congener dihydrochloride (XAC dihydrochloride) is a potentAdenosine A1 receptor and A2 receptorantagonist with IC50 values of 1.8 and 114nM, respectively. Xanthine amine congener acts as a convulsant agent in mi...

YN320141 PZM21 1997387-43-5

PZM21 is a potent and selectiveμ opioid receptoragonist with an EC50 of 1.8nM .

YN370942 JHU-083 1998725-11-3

JHU-083, a prodrug of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selectiveglutaminaseantagonist. JHU-083 blocks glutaminase activity in brain CD11b+cells and experimental cerebral malaria (ECM)...

YN371754 DSR-141562 2007975-22-4

DSR-141562 is a novel, orally active, and selective brain-penetrantphosphodiesterase 1 (PDE1)inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9nM, and theIC50 values for human PD...

YN320077 BMT-145027 2018282-44-3

BMT-145027 is anmGluR5positive allosteric modulator without inherent agonist activity, exhibits an EC50 of 47nM.

YN360268 JNJ-61432059 2035814-50-5

JNJ-61432059 is an oral active and selective negative modulator ofAMPARassociated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with apIC50 of 9.7 for GluA1/γ-8. Exhibits time- and dose-dependent AMP...

YN360405 BAY-1797 2055602-83-8

BAY-1797 is a potent, orally active, and selectiveP2X4antagonist, with an IC50 of 211nM against human P2X4. BAY-1797 displays no or very weak activity on the other P2X ion channels. BAY-1797 shows anti-nociceptive and ...

YN420127 BRD3731 2056262-07-6

BRD3731 is a selectiveGSK3βinhibitor, with IC50s of 15nM and 215nM for GSK3β and GSK3α, respectively. BRD3731 can be used for the research of a mood disorder, post-traumatic stress disorder (PTSD), psychiatric ...

YN420126 (R)-BRD3731 2056262-08-7

(R)-BRD3731 is aGSK3inhibitor extracted from patent US20160375006A1, compound example 273, hasIC50s of 1.05 and 6.7μM forGSK3β and GSK3α, respectively.

YN320661 BPR1M97 2059904-66-2

BPR1M97 is a dual-actingmu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptoragonist with Ki values of 1.8 and 4.2nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, ...

YN480456 DAAO inhibitor-1 2065250-25-9

DAAO inhibitor-1 is a potentD-amino acid oxidase (DAAO)inhibitor with an IC50 of 0.12μM.

YN321531 Hydroxyzine D4 2070014-84-3

Hydroxyzine D4 is deuterium labeled Hydroxyzine. Hydroxyzine is a heterocyclichistamine H1-receptorantagonist. Hydroxyzine has anticholinergic, anxiolytic and analgesic properties.

YN450005 SRI-011381 hydrochloride 2070014-88-7

SRI-011381 hydrochloride is an oral bioavailabileTGF-betasignaling agonist, exhibits neuroprotective effect.